18:02:00 EST Wed 18 Nov 2026
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Telo Genomics Corp (2)
Symbol TELO
Shares Issued 100,430,472
Close 2026-11-17 C$ 0.05
Market Cap C$ 5,021,524
Recent Sedar+ Documents

Telo signs term sheet for commercial licence option

2026-11-18 15:53 ET - News Release

Mr. John Price reports

TELO GENOMICS ANNOUNCES TERM SHEET PROVIDING AN OPTION FOR EXCLUSIVE WORLDWIDE LICENSE TO AI TECHNOLOGY FOR AUTOMATED DETECTION OF RARE MALIGNANT CELLS

Telo Genomics Corp. has signed a term sheet dated as of Aug. 20, 2026, providing an option to obtain an exclusive worldwide commercial licence with the University of Manitoba and Technion Research and Development Foundation Ltd., covering an artificial-intelligence method and system for the automated detection of low-concentration malignant cells in a biological sample, subject to negotiation and execution of a definitive licence agreement. No licence rights have been granted at this stage.

Under the contemplated definitive licence agreement, Telo Genomics would receive exclusive rights to make, use, sell and import licensed products and processes in the field of identifying, quantifying and analyzing cancer cells from human biological samples for cancer screening, clinical diagnosis, treatment selection and disease monitoring, including products that obtain FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), Health Canada or equivalent regulatory approval.

The AI method is designed to automatically identify rare malignant cells in a sample, a capability that is central to liquid-biopsy minimal residual disease (MRD) testing, where residual cancer cells may be present at extremely low frequency. The contemplated collaboration would, if a definitive licence agreement is executed, grant Telo Genomics exclusive rights to the jointly developed AI and is intended to support a more reproducible, scalable workflow for detecting circulating tumour cells before those cells are profiled on TeloView.

"This term sheet is a natural extension of the scientific collaboration that built Telo Genomics," said John Farlinger, chief executive officer and chairman of Telo Genomics. "Our platform already combines highly sensitive detection of circulating tumour cells with single-cell 3-D telomere analysis. Exercising the option and entering into a definitive licence agreement for this AI detection method, developed by the University of Manitoba and Technion, could help make that workflow faster, more reproducible and commercially scalable as we advance our multiple myeloma program and evaluate additional oncology applications.

"Detecting the right cell is the first step in any liquid-biopsy assay," said Mr. Farlinger. "Automating that step with AI reduces operator variability and supports the sensitivity required for MRD. Pairing automated cell identification with 3-D telomere profiling is consistent with our goal of giving clinicians both a count of residual disease and a readout of its biological aggressiveness."

The territory contemplated under the term sheet is worldwide. The field of use covers identification, quantification and analysis of cancer cells from human biological samples, including products that obtain regulatory approval. The term sheet provides an option for a contemplated exclusive worldwide licence within the specified field of use. No licence has been granted. Any grant of licence rights remains subject to negotiation and execution of a definitive licence agreement. There can be no assurance that a definitive agreement will be completed on the terms described or at all.

About Telo Genomics Corp.

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining the Telo Genomics team's considerable expertise in quantitative analysis of 3-D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of Telo Genomics' proprietary technology have been substantiated in more than 190 peer-reviewed publications and in more than 30 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Telo Genomics' lead application, Telo-MM, is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer.

We seek Safe Harbor.

© 2026 Canjex Publishing Ltd. All rights reserved.